Kodiak Sciences Inc.

NasdaqGM KOD

Kodiak Sciences Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2024

Kodiak Sciences Inc. EBITDA Margin is NA for the Trailing 12 Months (TTM) ending September 30, 2024. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NasdaqGM: KOD

Kodiak Sciences Inc.

CEO	Dr. Victor Perlroth M.D.
IPO Date	Oct. 4, 2018
Location	United States
Headquarters	1200 Page Mill Road
Employees	111
Sector	Consumer Discretionary
Industries Eyewear 3D Printing Augmented Reality (AR) Biotechnology Clinical Trials Glass Pharmaceuticals Vaccines

Description

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Key trends

Past 5 years